Iambic Therapeutics
PublicIambic Therapeutics is now publicly traded
The data on this page reflects Iambic Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series B
Sep 9, 2026
Total Funding Raised
$446.73M
Company Overview
Iambic Therapeutics is a biotechnology company that develops an AI-driven drug discovery platform to create novel medicines for cancer and other diseases.
Sector
Biotech
Verticals
Artificial Intelligence & Machine Learning, Digital Health, HealthTech, Life Sciences, Oncology
AI Layer
Application
Keywords
Iambic Therapeutics Comparables
Compare Iambic Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Genesis Therapeutics | 88% | |
| Valo Health | 87% | |
| Terray Therapeutics | 87% |
Iambic Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 9, 2026 | ||||
| Early Stage VC | Apr 8, 2026 | ||||
| VC Round | Nov 10, 2025 | ||||
| Series B Extension | Jun 18, 2024 | ||||
| Series B | Oct 3, 2023 | ||||
Series A | Jul 14, 2021 |
Key People
Founding team and executive leadership
Iambic Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| S32 | Series B |
| OrbiMed | Series B, Series A |
| Catalio Capital Management | Series B, VC Round, Series A |
| Freeflow Ventures | VC Round |
| Sequoia Capital | Series B, Series A, VC Round |
| Abingworth | Series B Extension, VC Round, Series B |
| Shanda Capital | Series B |
Recent news
Latest coverage and updates
- has_revenueOct 9, 2026
Iambic Therapeutics, Inc. reports $12.8M in revenue for the six months ended Jun 30th '26, alongside a US$50.1 million net loss.
- is_developingOct 9, 2026
Iambic Therapeutics, Inc. plans to continue developing its AI platform with $20m in IPO proceeds
- has_revenueOct 9, 2026
Iambic Therapeutics, Inc. reports $9.4M in collaboration revenue for 2025 in California
- is_developingSep 22, 2026
Iambic Therapeutics, Inc. is developing two earlier-stage programs designated IAM217 and IAM-C1 on Sep 21st '26.
- launchesSep 21, 2026
Iambic Therapeutics, Inc. launches next version of Enchant model.
Iambic Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access